Skip to main content

Providing independent clinical excellence since 2005

The SCVC Blog

Cardiovascular care news and articles from our expert team

What are the latest guidelines target for LDL?

Posted on Tuesday March 19, 2024 in Cholesterol & Atherosclerosis

Tags: Cholesterol, Coronary heart disease, CHD, PCSK9, Statin, LDL, search website using Tags to find related stories.

The latest European and UK guidelines reflect the finding that there is no lower limit for LDL yet discovered, basically meaning the lower the LDL the lower the risk of future cardiovascular events. These recommendations come after new trials with lower targets showed better outcomes. As a result, millions of people taking statins around the world need to be looking more carefully at whether they are taking sufficient medication to lower their LDL to these new targets if the very best outcomes are to be achieved.

table of LDL Targets from ESC

Summary table showing the target LDL recommended by  the European Society of Cardiology from reference [2] Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455

NHS and NICE approved pathways to prevent coronary heart disease in patients shown to be at increased risk

Some research suggests that non-HDL cholesterol may be a better predictor of heart disease than LDL cholesterol. This is because non-HDL cholesterol includes all the atherogenic lipoprotein particles, which transport triglycerides to tissues. These particles eventually turn into LDL. The NHS elected to simplify population blood testing for lipids, by measuring a random (non fasting) total blood cholesterol and HDL Cholesterol fraction. The term ‘non HDL cholesterol’  is widely used as an approximate equivalent to LDL and is simply derived by subtracting the HDL from Total Cholesterol.

For patients who have been diagnosed with an acute coronary syndrome, requiring bypass surgery or stent, or have CT Angiography and or raised FAI where the risk of future coronary events is increased, effective secondary prevention is required. The target LDL in such patients has been lowered to <1.8 mmol/L.

Download the guideline as PDF Locally-developed-Lipid-SCVC

  1. 2019 Guidelines on Dyslipidaemias (Management of) ESC Clinical Practice Guidelines
  2. European Society of Cardiology 2024: Lipidology update: targets and timing of well-established therapies

 

 

 

 

More articles for you

Who Can You Trust? The Rise of Anti-Statin Narratives and the Crisis of Trust in Modern Medicine

One of the greatest challenges in the online world is investigator bias. Any “expert” with a strong conviction — whether pro- or anti-statin — can easily find studies that appear to confirm their view. The internet is full of such cherry-picked data. When presented with confident authority, this can sound utterly convincing to a lay audience. The reality is that true medical understanding does not come from one paper, one YouTube video, or one self-proclaimed authority.

10 Things Everyone Who Has Had a Coronary Stent or Bypass Operation Should Know

Having a stent or bypass is not the end of the story—it is the beginning of a new chapter in managing your cardiovascular health. With the right combination of medications, lifestyle changes, rehabilitation programmes, and vigilant follow-up using advanced diagnostic techniques, you can greatly reduce your risk of future events. Stay engaged with your healthcare team, keep informed about new therapies and guidelines, and commit to sustainable lifestyle adjustments to ensure the best possible long-term health.

Why Cardiovascular Prevention Matters Before 30

Emerging evidence shows that lifetime exposure to LDL cholesterol and high glucose variability are some of the strongest predictors of cardiovascular risk. Just as lung cancer risk is tied to pack-years of smoking, heart disease risk correlates with cumulative LDL levels and glucose metrics such as HbA1c over time.This is why some people in their 20s with risk factors (like diabetes or a family history of heart disease) are starting statin therapy preventatively. However, many are understandably hesitant to start medication so early. Lifestyle changes remain the cornerstone of early prevention.